The RAAMP study. Ranibizumab versus aflibercept for age-related macular degeneration, using multifocal objective pupil perimetry.

This study is comparing two approved eye injections — ranibizumab (Lucentis) and aflibercept (Eylea) — for treating wet age-related macular degeneration (AMD), a condition that causes blurry or lost central vision in older adults. Researchers also want to test a new vision-testing tool called multifocal objective pupil perimetry (mfPOP) to see how well it tracks disease progress and treatment effects compared to standard testing methods. You may be eligible if: - You are 50 years of age or older - You have recently been diagnosed with wet AMD in one eye and have not yet been treated - You have some usable vision in the affected eye (at least 20 letters on an eye chart) You may NOT be eligible if: - Your other eye is currently receiving anti-VEGF injections for AMD or another condition - You have had anti-VEGF therapy in either eye within the last 6 months - You have ever had anti-VEGF treatment in the eye being studied - You have diabetes or any other disease known to affect the retina - You have glaucoma or another nerve condition in the study eye - You have had cataract surgery in the past 6 months, or are likely to need it within 2 years - You are highly short-sighted (myopic refraction of -6 diopters or worse) - You have a known allergy to ranibizumab or aflibercept Talk to your doctor about whether this trial might be right for you.